Page not found
HOME / Page not found

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (522)

Friday, 14 October 2022 21:00

Maria J. Serrano

Written by
Friday, 14 October 2022 21:00

Richa Dawar

Written by
Friday, 14 October 2022 10:03

Nagla Abdel Karim

Written by
Dr. Abdel Karim is the Director of the Phase I Program at Inova Schar Cancer Institute and Professor of Medicine-University of Virginia. Her clinical and research interests are focused on Phase I clinical trials and the personalized approach of therapy for lung cancer. She is the study chair of S1929 clinical trial at SWOG that focuses on personalized therapy for SLFN11 small cell lung cancer. Dr. Nagla Abdel Karim received her Medical degree from the University of Cairo- Faculty of Medicine. She subsequently received her training in Internal Medicine/Medical Oncology at the National Cancer Institute-The University of Cairo and she obtained her Masters of Science degree followed by PhD, where the latter was through a channel program with the University of Washington. She did a year of Post-doctoral fellowship at MD Anderson in Cancer Prevention, followed by one-year Research fellowship at The University of Washington. She did a residency in Internal Medicine at Fairview-Cleveland Clinic Hospitals in Cleveland, Ohio followed by a 3-year clinical fellowship in Hematology/Oncology at The University of Cincinnati then became Assistant Professor of Medicine at Ohio State University then re-joined the University of Cincinnati again in September 2011 as an Assistant Professor then Associate Professor till 2018. She has been the Professor of Medicine-Division of Hematology/Oncology and the Director of the Thoracic Oncology at the Medical College of Georgia-Augusta-Georgia since 2018 till 2022. During all that time, she was an Investigator and Co- investigators of several Clinical Trials as well as a lead investigator on several translational research projects.
Friday, 14 October 2022 10:03

Ariane Hallermayr

Written by
Friday, 14 October 2022 10:03

Lauren Leiman

Written by
Friday, 14 October 2022 10:03

Dana Connors

Written by
Dana E. Connors, MSc, PMP is the Senior Scientific Program Manager for Cancer Research Partnerships at the Foundation for the National Institutes of Health. Drawing on experience in the biotechnology industry, non-profit and federal sectors, he works with Biomarkers Consortium members to set strategy and prioritize project pipelines for cancer initiatives and manages the activities of project teams and working groups to facilitate the advancement and execution of innovative cancer research and biomarker development. In his work with public-private biomedical research partnerships he engages participation from government, industry, academia, patient-advocacy, and private sector organizations to drive international scientific collaboration in multiple disease areas. Ongoing collaborations include analytical validation and clinical utility of liquid biopsy, project opportunities in immuno-oncology biomarkers, development of clinical trial metrics, and Minimal Residual Disease in blood-based cancers.
Friday, 14 October 2022 10:03

Karen Kelly

Written by
Friday, 14 October 2022 10:03

Jean-Francois Pouliot

Written by
Dr. Pouliot completed a doctoral degree at the University of Montreal in Human Physiology, followed by a fellowship at McGill University on multidrug resistance in cancer. With broad experience in clinical development, he worked on numerous phase I – III programs leading to innovative drug approvals, including Imatinib in chronic myelogenous leukemia, Temozolomide in brain tumors, and Pembrolizumab in melanoma and lung cancer. Hover the years, fostered numerous academia-industry collaborations and investigator-driven initiatives across the Americas, Europe, and Asia. At Regeneron Pharmaceuticals, he leads the global medical affairs team in lung cancer and other solid tumors.
Page 28 of 38